Who is sponsoring NCT07317934?

NCT07317934 is sponsored by Innostellar Biotherapeutics Co.,Ltd.

What condition does NCT07317934 study?

NCT07317934 studies Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD.

What drugs are being tested in NCT07317934?

Interventions: LX102, Aflibercept.

What is the status of NCT07317934?

NCT07317934 is currently RECRUITING.

Last reviewed 2026-03-04 · How we verify

A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants With Neovascular Age-Related Macular Degeneration - The STELLAR Trial

NCT07317934 Phase 3 RECRUITING

This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. The primary endpoint of this study is the mean change from D0 in BCVA based on an average at weeks 40 and 48.

Details

Lead sponsor	Innostellar Biotherapeutics Co.,Ltd
Phase	Phase 3
Status	RECRUITING
Enrolment	332
Start date	2026-01-14
Completion	2032-06-04

Conditions

Neovascular Age-Related Macular Degeneration (nAMD)
Wet AMD

Interventions

LX102
Aflibercept

Primary outcomes

Mean change from D0 in BCVA based on an average at weeks 40 and 48. — Weeks 40 and 48
Mean change from D0 in BCVA as measured by the early treatment diabetic retinopathy study (ETDRS) visual acuity chart based on an average at weeks 40 and 48.

Countries

China